Clinical Professor of Medicine, UCLA
Rheumatology
Dr. Daniel J. Wallace, MD
|
|
Give Review
Daniel J. Wallace, MD works in the field of Rheumatology. He researched medicine at Keck School of Medicine of USC. Keck School of Medicine of USC is ranked 31 in research and 72 in primary care medicine He has 6 awards "America's Top Doctors", "Top Doctors:LA Area", "CMS Meaningful Use Stage 1 Certification", "Top Doctors:Southern California", "Fellow (FACR)" and "Super Doctor". Daniel Wallace is a published MD as well. He has 77 publications published. The latest was: Previous diagnosis of Sjgren's Syndrome as rheumatoid arthritis or systemic lupus erythematosus. Dr. Daniel J. Wallace accepts Medicare.
Publications
- Chest Pain in lupus patients: the emergency department experience.
- Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices.
- Anti-C1q antibodies in systemic Lupus erythematosus.
- Cytokine and chemokine profiles in fibromyalgia, rheumatoid Arthritis and systemic lupus erythematosus: a potentially useful tool in differential diagnosis.
- Development and validation of the Lupus impact tracker: a patient-completed tool for clinical practice to assess and monitor the impact of systemic Lupus erythematosus.
- Factors associated with damage accrual in patients with systemic Lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Incep...
- American College of Rheumatology Criteria at Inception, and Accrual over 5 Years in the SLICC Inception Cohort.
- A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic Lupus erythematosus.
- Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE tri...
- Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus.
- Ten developments in the use of biologicals for systemic Lupus erythematosus.
- Quality guidelines for systemic Lupus erythematosus: slow but steady progress.
- Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic Lupus erythematosus: results from two randomized, double-blind, placebo-controlled...
- Sifalimumab, a human anti-interferon-a monoclonal antibody, in systemic Lupus erythematosus: A phase 1 randomized controlled, dose-escalation study.
- Predictors of preterm birth in patients with mild systemic Lupus erythematosus.
- Efficacy and safety of epratuzumab in patients with moderate/severe active systemic Lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, pl...
- Safety and pharmacodynamics of rontalizumab in patients with systemic Lupus erythematosus: Results of a phase I, placebo-controlled, double-blind, dose-escalation study.
- New insights into mechanisms of therapeutic effects of antimalarial agents in SLE.
- Effect of Belimumab on Vaccine Antigen Antibodies to Influenza, Pneumococcal, and Tetanus Vaccines in Patients with Systemic Lupus Erythematosus in the BLISS-76 Trial.
- American College of Rheumatology guidelines for screening, treatment, and management of Lupus nephritis.
- A brief assessment tool for body image in systemic Lupus erythematosus.
- Sex chromosome aneuploidies among men with systemic Lupus erythematosus.
- Prescribing trends for targeted therapies in rheumatoid Arthritis among rheumatologists in Southern California (2008-2010).
- High plasma leptin levels confer increased risk of atherosclerosis in women with systemic Lupus erythematosus, and are associated with inflammatory oxidised lipids.
- Neuroimaging evidence of white matter inflammation in newly diagnosed systemic Lupus erythematosus.
- Myocardial ischemia in the absence of obstructive coronary artery Disease in systemic lupus erythematosus.
- Thrombovascular events in systemic Lupus erythematosus: comment on the article by Jung et al.
- Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid Arthritis with an inadequate response to one or more disease-modifying antirheumatic dru...
- Telomere Diseases.
- Low physical activity is associated with proinflammatory high-density lipoprotein and increased subclinical atherosclerosis in women with systemic Lupus erythematosus.
- Lupus registries: evolution and challenges.
- Efficacy and safety of rituximab in moderately-to-severely active systemic Lupus erythematosus: the randomized, double-blind, phase II/III systemic Lupus erythematosus...
- A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic Lupus erythematosus.
- Novel evidence-based systemic Lupus erythematosus responder index.
- Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic Lupus erythematosus.
- Are there models for predicting accelerated atherogenesis in systemic Lupus erythematosus?
- Celecoxib for Lupus.
- Additional components to measuring fatigue in patients with systemic Lupus erythematosus: comment on the article by the Ad Hoc Committee on systemic Lupus erythematosu...
- Clinical validation of the watershed sign as a marker for neuropsychiatric systemic Lupus erythematosus.
- Hypothesis: bipolar illness with complaints of chronic musculoskeletal pain is a form of pseudoFibromyalgia.
- Association of a common complement receptor 2 haplotype with increased risk of systemic Lupus erythematosus.
- Retraction of the suggestion to use the term "Reiter's Syndrome" sixty-five years later: the legacy of Reiter, a war criminal, should not be eponymic honor b...
- What's new in the management of Lupus since 2000?
- Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid Arthritis.
- New methods for antinuclear antibody testing: does it cut costs and corners without jeopardizing clinical reliability?
- Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid Arthritis.
- Is mycophenolate mofetil a safe and effective treatment for patients with systemic Lupus erythematosus?
- Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid Syndrome.
- Chronic inflammatory demyelinating polyneuropathy in patients with systemic Lupus erythematosus: prognosis and outcome.
- Mycophenolate mofetil or intravenous cyclophosphamide for Lupus nephritis.
- Association analysis of the R620W polymorphism of protein tyrosine phosphatase PTPN22 in systemic Lupus erythematosus families: increased T allele frequency in systemi...
- Photoemission studies of polythiophene and polyphenyl films produced via surface polymerization by ion-assisted Deposition.
- Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic Arthritis: results from the infliximab multinational psoriatic arth...
- Rapid prevention of vertebral fractures associated with Osteoporosis.
- Whiplash: a case of regretting being responsible for naming a condition.
- Eligibility, utilization, and costs in a California Medicaid Lupus population.
- The end of an era: a commentary on the demise of the bulletin on rheumatic Diseases (1950-2004).
- Railway spine, posttraumatic Fibromyalgia, and junk science in the courtroom (ca. 1975).
- Fibromyalgia: the gastrointestinal link.
- Fever therapy for Arthritis.
- The management of chronic noninfectious synovitis ca. 1818.
- When thought leaders mislead: "Discoid lupus is not related to SLE".
- Historical vignette: Raynaud's phenomenon as perceived by musculoskeletal specialists (1862-1957).
- The physician Hans Reiter as prisoner of war in Nuremberg: a contextual review of his interrogations (1945-1947).
- Pyridostigmine for Fibromyalgia: comment on the article by Paiva and a historical vignette.
- Linkage and interaction of loci on 1q23 and 16q12 may contribute to susceptibility to systemic Lupus erythematosus.
- Familiality and co-occurrence of clinical features of systemic Lupus erythematosus.
- Silicone breast implants do not cause rheumatic Diseases, but can they influence them?
- Management of Lupus erythematosus: recent insights.
- The management of Fibromyalgia-associated syndromes.
- A Prevalence Survey of Lupus in Moorpark, California Is There Any Evidence for a Lupus Cluster?
- Spanish LupusPRO: cross-cultural validation study for Lupus.
- Cumulative corticosteroids over 52 weeks in patients with systemic Lupus erythematosus: Pooled analyses from the phase III belimumab trials.
- Previous diagnosis of Sjögren's Syndrome as rheumatoid Arthritis or systemic lupus erythematosus.
- Efficacy and safety of subcutaneous tabalumab in patients with systemic Lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, ...
- Systemic lupus erythematosus and primary Fibromyalgia can be distinguished by testing for cell-bound complement activation products.
Schools
University of Southern California Keck School of Medicine
Procedures Preformed
- Joint Drainage
- Myofascial Trigger Point Injection
- Non-Spinal Nerve Blocks
- Steroid Injection
- View All
Conditions Treated
- Ankylosing Spondylitis
- Arthritis
- Behçet's Disease
- Bursitis
- View All
Doctors Specialties
- Rheumatology
Accepted Insurances
- Aetna
- Assurant Health
- Blue Card PPO
- Advantage Preferred DirectAccess Plus PPO
- Blue Cross Blue Shield of California PPO
- Pathway X Direct Access PPO
- Pathway X Tiered Direct Access
- Access Plus Savenet
- Basic PPO
- Cigna
- Commercial Insurance Company
- CoreSource
- Coventry Health Care
- Delta Health System
- Golden Rule
- GEHA
- Group Health Cooperative
- Medicare Advantage PFFS
- Kaiser Permanente
- Medicaid
- Medicare MCR
- MultiPlan
- Heritage Signature
- United Healthcare
Awards
- America's Top Doctors
- Top Doctors:LA Area
- CMS Meaningful Use Stage 1 Certification
- Top Doctors:Southern California
- Fellow (FACR)
- Super Doctor
Education
-
Cedars-Sinai Medical Center -
Brown University -
Keck School of Medicine of USC
Hospital
-
Ronald Reagan UCLA Medical Center -
Cedars-Sinai Medical Center
Drug Facts
| NPI NUMBER | 1982608717 | |
| NPPES Provider LastName | WALLACE | |
| NPPES Provider FirstName | DANIEL | |
| NPPES Provider ZIPCode | 900481840 | |
| NPPES Provider State | CA | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 4072.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 227.0 | |
| Percent Opioid Claims | 5.57 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1982608717 |
| Last Name Of The Provider | WALLACE |
| First Name Of The Provider | DANIEL |
| View All |
Similar Doctors
|
Dr. Swamy Venuturupalli, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joel Schneider, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Benjamin R. Kretzmann, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shirin Bagheri, MD |
|
|
Dr. Gita Fatemi, MD
This Doctor is OpenDoctor Recommended.
|